AstraZeneca to launch CRISPR-based cancer research centre

Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

CRISPR babies still too risky, warns new report

10 September 2020 Human embryos whose genomes have been edited should not be used to create a pregnancy until it is certain that changes can be made without introducing undesired changes, according to a new report by an influential panel.

Big Pharma

AstraZeneca and Daiichi Sankyo to develop new cancer treatment

2 April 2019 Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.

Biotechnology

Cancer Research UK forms immunotherapy alliance

28 March 2019 Cancer Research UK has formed a multimillion-pound drug discovery alliance with fellow charity LifeArc and Japanese company Ono Pharmaceutical.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

AstraZeneca to launch CRISPR-based cancer research centre

More on this story

Editor's picks

Editor's picks

More features